All > Metastatic Triple Negative Breast Cancer > Triple Negative Breast Cancer

Alkylating agents

Triple Negative Breast Cancer (for tumors > 5 cm) for Breast Cancer

Q: Are there any positions available in this trial for new patients?

<p>Unfortunately, this particular trial is no longer recruiting patients. Although the last update was on May 15th, 2022, it was originally posted on June 15th of the same year. There are plenty of other trials, however; 7278 to be exact.</p>

Q: How many volunteers are taking part in this experiment?

<p>Unfortunately, this particular study is not currently looking for more participants. Although, it's worth mentioning that there are 5074 other trials related to triple negative <a href="https://www.withpower.com/clinical-trials/breast">breast</a> neoplasms and 2204 trials concerning Triple Negative Breast Cancer (for tumors > 5 cm) that are actively recruiting patients right now.</p>

O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston, TX

Targeting 11 different conditionsCarboplatin +7 morePhase 2RecruitingLed by Mothaffar Rimawi, MDResearch Sponsored by Baylor Breast Care Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up20 weeks

Awards & highlights

All Individual Drugs Already Approved

Approved for 20 Other Conditions

No Placebo-Only Group

Study Summary

This trial will study whether the amount a tumor shrinks before surgery can predict how much of the tumor will remain after surgery.

Eligible Conditions

Breast Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 20 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~20 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Clinical Tumor Measurement vs. Pathologic Response

Secondary outcome measures

Pathologic Complete Response Rate in each Breast Cancer Subtype

Pharmacotherapy

Other outcome measures

Change in circulating tumor DNA (ctDNA) levels from baseline to surgery

Awards & Highlights

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Approved for 20 Other Conditions

This treatment demonstrated efficacy for 20 other conditions.

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups

Active Control

Group I: Triple Negative Breast Cancer (for tumors > 5 cm)Active Control5 Interventions

Paclitaxel IV plus carboplatin IV (+/- pembrolizumab IV) (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (+/- pembrolizumab IV) (4 cycles total)

Group II: Triple Negative Breast Cancer (for tumors < 5 cm)Active Control3 Interventions

Paclitaxel IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)

Group III: HER2-Positive Breast CancerActive Control6 Interventions

Paclitaxel IV plus Trastuzumab IV plus Pertuzumab IV (or PHESGO) (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV administered (4 cycles total)

Group IV: Hormone Receptor Positive Breast CancerActive Control3 Interventions

Paclitaxel IV plus Carboplatin IV (4 cycles total), followed by doxorubicin IV plus cyclophosphamide IV (4 cycles total)

Do I qualify?Apply below to find out

Find a site

Who is running the clinical trial?

Baylor Breast Care CenterLead Sponsor

15 Previous Clinical Trials

597 Total Patients Enrolled

11 Trials studying Breast Cancer

501 Patients Enrolled for Breast Cancer

Mothaffar Rimawi, MDPrincipal Investigator

Baylor College of Medicine

14 Previous Clinical Trials

781 Total Patients Enrolled

10 Trials studying Breast Cancer

649 Patients Enrolled for Breast Cancer

Media Library

Carboplatin (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT05020860 — Phase 2

Breast Cancer Research Study Groups: Triple Negative Breast Cancer (for tumors > 5 cm), Triple Negative Breast Cancer (for tumors < 5 cm), HER2-Positive Breast Cancer, Hormone Receptor Positive Breast Cancer

Breast Cancer Clinical Trial 2023: Carboplatin Highlights & Side Effects. Trial Name: NCT05020860 — Phase 2

Carboplatin (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05020860 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any positions available in this trial for new patients?

"Unfortunately, this particular trial is no longer recruiting patients. Although the last update was on May 15th, 2022, it was originally posted on June 15th of the same year. There are plenty of other trials, however; 7278 to be exact."

Answered by AI

How many volunteers are taking part in this experiment?

"Unfortunately, this particular study is not currently looking for more participants. Although, it's worth mentioning that there are 5074 other trials related to triple negative breast neoplasms and 2204 trials concerning Triple Negative Breast Cancer (for tumors > 5 cm) that are actively recruiting patients right now."

Answered by AI

Is this a groundbreaking clinical trial?

"Since 1997, there have been 2204 ongoing studies and 2978 completed trials for Triple Negative Breast Cancer (for tumors > 5 cm) across 87 countries and 4024 cities."

Answered by AI

What is the most common treatment for Triple Negative Breast Cancer (for tumors > 5 cm)?

"While most often used to treat acute lymphoblastic leukemia, triple negative breast cancer can also help patients dealing with neoplasm metastasis, cyclophosphamide, lymphoma, and non-hodgkin."

Answered by AI

Does the FDA condone Triple Negative Breast Cancer treatments for patients with tumors larger than 5 cm?

"For Triple Negative Breast Cancer (for tumors > 5 cm), our team has given it a score of 2. This is because while there is some data indicating that the intervention might be safe, at this stage there is no evidence to support efficacy."

Answered by AI

Are there any other documented cases of research done on Triple Negative Breast Cancer (for tumors larger than 5 cm)?

"2204 studies are currently underway to research Triple Negative Breast Cancer (for tumors > 5 cm), with 507 of them in the critical Phase 3. Most of these investigations into Triple Negative Breast Cancer (for tumors > 5 cm) are based in Seattle, Washington, but there are 95200 locations running clinical trials for Triple Negative Breast Cancer (for tumors > 5 cm)."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Mothaffar Rimawi 2023. "Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05020860.